Paris/France—January 8, 2021: Biomillenia and Amyris, Inc., a leading synthetic biotechnology company in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty, and Flavors & Fragrances markets, announced today the signing of a R&D collaboration agreement aiming to evaluate Biomillenia’s microfluidics-based culture platform for phenotypic screening of Amyris’s engineered production strains. Biomillenia will contribute its unique lab-on-a-chip technology that has the ability to culture microorganisms and cells in millions of parallel tiny droplets in a single experiment that can be subsequently screened at ultrahigh-throughput for phenotypic changes of the contained organisms. The technology will allow Amyris to identify and select improved producers from millions of engineered organisms, improving throughput of current technology by over 100-fold.
“Amyris is excited to partner with Biomillenia to evaluate its droplet microfluidics platform. When successfully implemented, this technology will add significant testing capacity to our pipeline, allowing many millions of cells to be tested each day decreasing cell line development time and improving time to market.”
said Michael Leavell, Vice President R&D, Amyris Inc.
“The collaboration agreement with Amyris shows the great attractiveness of the Biomillenia ultrahigh-throughput digital culturomics and screening platform for the identification and selection of organisms at a scale that cannot be realized with any other platform technology. We leverage our proprietary platform across several industries. Applications range from the discovery of novel microorganisms from environmental and patient samples to the screening of non-GMO or engineered production strains for improved productivity. We are supporting companies in various industry sectors including agriculture, consumer health, personal care and animal health and food by providing access to our technology platform to culture and perform functional analysis of microorganisms in millions of low volume droplets at a time. In addition, our customers can gain access to our microbial culture collection and state of the art microbe isolation and sequencing technologies,”
said Dirk Loeffert, Ph.D., CEO of Biomillenia.
Amyris is a science and technology leader in the research, development and production of sustainable ingredients for the Clean Health & Beauty and Flavors & Fragrances markets. Amyris uses an impressive array of exclusive technologies, including state-of-the-art machine learning, robotics and artificial intelligence. Our ingredients are included in over 3,000 products from the world’s top brands, reaching more than 200 million consumers. Amyris is proud to own three consumer brands—all built around its No Compromise® promise of clean ingredients: Biossance™ clean beauty skincare, Pipette™ clean baby skincare and Purecane™, a zero-calorie sweetener naturally derived from sugarcane. For more information, please visit www.amyris.com.
Biomillenia harnesses smart microbes to restore the body’s healthy balance and help prevent lifestyle diseases. Using its proprietary technology platform, the company is able to isolate strains of beneficial microbes based on their functional traits at speeds and in volumes that to date have not been feasible. Biomillenia’s core strategy is to incorporate these smart microbes or compounds thereof into consumer or therapeutic products. Biomillenia also offers its microbiome platform to leading industry players in collaborative projects. The company is based in Romainville, France. Further information at www.biomillenia.com.